Drug discovery and development – Page 24
-
OpinionNatural selection
Bioactive compounds don’t just inspire new synthetic strategies, they’re also the ultimate test
-
OpinionRise of the biologics
Antibodies, RNA and gene therapy don’t necessarily compete with small molecule drugs – and they all rely on chemistry
-
BusinessUS to invest $160m in cancer partnership
Funds will be backed up with $55m from 11 companies to advance new cancer treatments that harness the immune system
-
WebinarFuture chemistry: exploring the possibility space
Find out how to accelerate discovery by understanding vast and complex chemistry problems with visual and predictive data modelling
-
CareersVideo games are enabling discovery
Gamification is harnessing an untapped army of citizen scientists
-
FeatureThe long road to an HIV vaccine
A vaccine may not be available anytime soon, but its proponents are hard at work
-
ResearchSuper-electrophilic ions enable selective modification of bioactive molecules
New technique will help medicinal chemists explore chemical space
-
OpinionAn opportunity ignored
Dismissing ideas that were ‘not invented here’ is like walking past a $100 bill
-
BusinessTakeda tightens focus on core areas with multiple deals
Japanese firm is remodelling its R&D efforts through collaboration and licensing deals, and selling off non-core businesses
-
ArticlePharma supply chains pick up pace
Contract suppliers are increasingly important in reducing time to market
-
ArticleIn-house training speeds up metabolism
Business plugs DMPK skills gap to improve drug discovery
-
FeatureThe rising tide of 'legal highs'
Andy Extance investigates the chemistry that has helped recreational drugs evade the law, and its consequences
-
OpinionMake room for randomness in drug development
Setting free the dark horses sometimes beats the most rational planning
-
WebinarCurrent topics in bioconjugation
Insights into making bioconjugates using optimal reagents and the latest techniques to create highly active and stable complexes
-
FeatureEnvironmentally benign by design
The challenge of designing drugs with biodegradability in mind
-
ResearchSingle-cell imaging spots resistant infections in less than half an hour
Microfluidic device allows speedy susceptibility testing so the right antibiotic can be given
-
ResearchStructural sleuthing salvages superbug slayer
Combining ‘assembly line’ synthesis, spectroscopy and computational predictions solves stereochemistry riddle
-
ResearchPlotting a course to new antibiotics
Mapping out the chemical space of peptide antibiotics offers an efficient way to find new compounds
-
BusinessAstraZeneca shares tumble after antibody failure
Imfinzi and tremelimumab checkpoint inhibitor pairing fails to beat chemotherapy in lung cancer
-
BusinessNovartis coasts towards first CAR-T approval
Unanimous recommendation for CTL019 ahead of October decision builds confidence in T-cell genetic reprogramming